Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.
- 2022-10
- RCT · n = 92
- Current pharmaceutical design 28(38)
- Giulia Malaguarnera
- Vito Emanuele Catania
- Gaetano Bertino
- Laura Maria Chisari
- Maria Castorina
- Claudia Bonfiglio
- Omar Cauli
- Michele Malaguarnera
- PubMed: 36043711
- DOI: 10.2174/1381612828666220830092815
- High evidence
- Clinical
increase in 6-walking distance (p < 0.0001); ALCAR group vs. placebo group showed an increase in the 6-walking distance (p < 0.001)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 1.5 g BID